{"protocolSection":{"identificationModule":{"nctId":"NCT06474650","orgStudyIdInfo":{"id":"LY03015/CT-CHN-103"},"organization":{"fullName":"Luye Pharma Group Ltd.","class":"INDUSTRY"},"briefTitle":"Effect of Food on the Pharmacokinetics of LPM3770164 Sustained-release Tablets","officialTitle":"A Randomized, Open-label, Two-period, Double-crossover Phase 1 Study to Evaluate the Effect of Food on the Pharmacokinetics of LPM3770164 Sustained-release Tablets in Healthy Subjects"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-08","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2024-09","type":"ESTIMATED"},"completionDateStruct":{"date":"2024-10","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-20","studyFirstSubmitQcDate":"2024-06-20","studyFirstPostDateStruct":{"date":"2024-06-25","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-06-20","lastUpdatePostDateStruct":{"date":"2024-06-25","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Luye Pharma Group Ltd.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This is a A single-center, randomized, open-label, two-dose, two-period, crossover trial was conducted to evaluate the effect of food on the Pharmacokinetic characteristics and safety of oral administration of LPM3770164 sustained-release tablets 30 mg in healthy subjects."},"conditionsModule":{"conditions":["Huntington Disease","Tardive Dyskinesia"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"CROSSOVER","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":16,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Fed condition","type":"EXPERIMENTAL","description":"Period in which subjects receive a single oral dose of LPM3770164 sustained-release tablets in fed condition","interventionNames":["Drug: LPM3770164 sustained release tablet"]},{"label":"Fasted condition","type":"EXPERIMENTAL","description":"Period in which subjects receive a single oral dose of LPM3770164 sustained-release tablets in fasted condition","interventionNames":["Drug: LPM3770164 sustained release tablet"]}],"interventions":[{"type":"DRUG","name":"LPM3770164 sustained release tablet","description":"Single-dose of 30 mg of LPM3770164 sustained release tablet","armGroupLabels":["Fasted condition","Fed condition"],"otherNames":["LY03015"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Peak Plasma Concentration (Cmax)","timeFrame":"Predose and up to 240 hours postdose"},{"measure":"Area Under the Curve from time 0 to the last measurable concentration (AUC0-t)","timeFrame":"Predose and up to 240 hours postdose"},{"measure":"Area Under the Curve from time 0 extrapolated to infinity (AUC0-inf)","timeFrame":"Predose and up to 240 hours postdose"}],"secondaryOutcomes":[{"measure":"Treatment-emergent adverse event","timeFrame":"from baseline to day 25"},{"measure":"Time to maximum concentration (Tmax)","timeFrame":"Predose and up to 240 hours postdose"},{"measure":"Half-life (t1/2)","timeFrame":"Predose and up to 240 hours postdose"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Subject who voluntarily participate and sign the informed consent form;\n2. Healthy male/female volunteers aged 18 to 45 years;\n3. Body weight ≥ 50.0 kg for men and ≥ 45.0 kg for women, and body mass index (BMI) 18.5 \\~ 26.0 kg/m2, inclusive;\n4. Able to comply with the lifestyle restrictions.\n\nExclusion Criteria:\n\n1. Subject has a history of allergy to any component of the investigational drug or similar drugs, or allergic constitution;\n2. Subject has a current or past medical history that may affect the clinical trial or dysfunction, including but not limited to the past or current respiratory system, circulatory system, digestive system, urinary system, reproductive system, nervous system, endocrine system, immune system, motor system, blood system, psychiatry/ psychology, dermatology and other clinically serious diseases or chronic diseases; or any other diseases that may interfere with the test results;\n3. Any surgical condition or condition may significantly affect the absorption, distribution, metabolism and excretion of the drug, or may pose a hazard to the subjects;.\n4. Subject has a history of self-mutilation; or at risk of suicide;\n5. Subject has a history of surgery within 3 months prior to administration, or failure to recover from surgery, or having an expected surgical plan during the trial;\n6. Subject has abnormal vital signs, laboratory abnormalities, and ECGs;\n7. Subject has used any of over-the-counter products within 7 days or prescription medications within 28 days prior to dosing;\n8. Subject positive for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV-Ab), HIV antibody (HIV-Ab), or syphilis seroreactivity (Trust);\n9. Subject has a history of alcohol abuse within 1 year or positive alcohol breath test results;\n10. Subject has a history of substance abuse within 1 year or a positive urine drug screen;\n11. Subject who has daily smoking of ≥ 5 cigarettes within 3 months;\n12. Subject who has special requirements for food, cannot comply with the unified diet or have dysphagia\n13. Subject who has consumption of xanthine-rich foods or beverages (such as tea, coffee, cola, or chocolate) within 3 days prior to administration;\n14. Subject who has consumption of food or beverages containing grapefruit within 7 days prior to administration;\n15. Subject who has participated in other clinical trials and were enrolled/randomized within 3 months before administration;\n16. Subject has used blood products or being blood donor or blood loss within 3 months;\n17. Pregnant, lactating women, or positive pregnancy test;\n18. Subject who refusal to contraception, or plan to donate sperm or ovums;\n19. Other conditions which would make participation in the study unsuitable","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"45 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Hufang Li, Doctor","role":"CONTACT","phone":"+8618017311256","email":"lhlh_5@163.com"}],"overallOfficials":[{"name":"Hufang Li, Doctor","affiliation":"Shanghai Mental Health Center","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Shanghai Mental Health Center","city":"Shanghai","country":"China","contacts":[{"name":"Huafang Li","role":"CONTACT"},{"name":"Huafang Li Li, Doctor","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Yimin Yu, Doctor","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":31.22222,"lon":121.45806}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"meshes":[{"id":"D000020820","term":"Dyskinesias"},{"id":"D000006816","term":"Huntington Disease"},{"id":"D000071057","term":"Tardive Dyskinesia"}],"ancestors":[{"id":"D000009069","term":"Movement Disorders"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000009461","term":"Neurologic Manifestations"},{"id":"D000001480","term":"Basal Ganglia Diseases"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000003704","term":"Dementia"},{"id":"D000002819","term":"Chorea"},{"id":"D000020271","term":"Heredodegenerative Disorders, Nervous System"},{"id":"D000019636","term":"Neurodegenerative Diseases"},{"id":"D000030342","term":"Genetic Diseases, Inborn"},{"id":"D000003072","term":"Cognition Disorders"},{"id":"D000019965","term":"Neurocognitive Disorders"},{"id":"D000001523","term":"Mental Disorders"},{"id":"D000004409","term":"Dyskinesia, Drug-Induced"}],"browseLeaves":[{"id":"M22574","name":"Dyskinesias","asFound":"Dyskinesia","relevance":"HIGH"},{"id":"M9875","name":"Huntington Disease","asFound":"Huntington's Disease","relevance":"HIGH"},{"id":"M680","name":"Tardive Dyskinesia","asFound":"Tardive Dyskinesia","relevance":"HIGH"},{"id":"M12029","name":"Movement Disorders","relevance":"LOW"},{"id":"M5742","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M12404","name":"Neurologic Manifestations","relevance":"LOW"},{"id":"M25603","name":"Ganglion Cysts","relevance":"LOW"},{"id":"M16358","name":"Synovial Cyst","relevance":"LOW"},{"id":"M4774","name":"Basal Ganglia Diseases","relevance":"LOW"},{"id":"M5204","name":"Brain Diseases","relevance":"LOW"},{"id":"M6904","name":"Dementia","relevance":"LOW"},{"id":"M6059","name":"Chorea","relevance":"LOW"},{"id":"M22092","name":"Heredodegenerative Disorders, Nervous System","relevance":"LOW"},{"id":"M21558","name":"Neurodegenerative Diseases","relevance":"LOW"},{"id":"M23686","name":"Genetic Diseases, Inborn","relevance":"LOW"},{"id":"M6301","name":"Cognition Disorders","relevance":"LOW"},{"id":"M21836","name":"Neurocognitive Disorders","relevance":"LOW"},{"id":"M14473","name":"Psychotic Disorders","relevance":"LOW"},{"id":"M4815","name":"Mental Disorders","relevance":"LOW"},{"id":"M7583","name":"Dyskinesia, Drug-Induced","relevance":"LOW"},{"id":"T2852","name":"Huntington Disease","asFound":"Huntington's Disease","relevance":"HIGH"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC16","name":"Diseases and Abnormalities at or Before Birth"},{"abbrev":"BXM","name":"Behaviors and Mental Disorders"},{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"BC17","name":"Skin and Connective Tissue Diseases"},{"abbrev":"BC25","name":"Substance Related Disorders"},{"abbrev":"Rare","name":"Rare Diseases"}]}},"hasResults":false}